PCI Biotech initiates research collaboration with IMV Inc

Posted on May 24, 2018

Exploring synergies between PCI and DPX technologies to further enhance the effect of novel oncologic therapies

Oslo (Norway) 24 May 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that it is initiating a preclinical research collaboration with IMV Inc (TSE:IMV) (OTCQX:IMMVD) Nova Scotia (Canada), a clinical stage biopharmaceutical corporation focused on developing state-of-the-art immunotherapies. The partnership is governed by a preclinical research collaboration agreement.

In brief, the collaborators will evaluate the formulation compatibility of their respective technologies and evaluate the potential immunogenicity and therapeutic benefit with in vivo studies. Based upon the results, the companies may pursue a further development partnership.

Per Walday, CEO of PCI Biotech, said: “I’m very pleased to announce another research agreement in the field of nucleic acid therapeutics. We believe that the PCI technology has the potential to play a role in the realisation of several new therapeutic modalities. We look forward to explore synergies with IMV’s unique and innovative DPX technology.”

Contact information:
Per Walday, CEO
pw@pcibiotech.com
Mobile: +47 917 93 429

About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.  PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fimaCHEM programme consists of a clinical Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products.  fimaVACC applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies.  fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.